In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions, with a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including Emergent Biosolutions’ recent financial performance and strategic advancements. Despite a revenue miss in the second quarter of 2025, the company narrowed its net loss more than expected, showing a modest bottom-line beat. The tightening of the full-year revenue guidance range and the improvement in gross margin percentages indicate potential operational improvements for the remainder of the year.
Additionally, key developments such as the $65 million contract with Ontario’s Ministry of Health for NARCAN Nasal Spray and the expansion of NARCANDirect highlight the company’s strong portfolio value. Emergent’s strategic contract modifications for Botulism Antitoxin and Vaccinia Immune Globulin, along with its inclusion in the Russell 3000 Index, further bolster its market position. The increase in revenues from smallpox medical countermeasure products and potential growth in usage of its antiviral brincidofovir due to recent clinical data also support the positive outlook. These factors collectively underpin Selvaraju’s Buy rating and the 12-month price target of $15.
In another report released on August 8, Benchmark Co. also maintained a Buy rating on the stock with a $12.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EBS in relation to earlier this year.